BioLineRX
BLRX
23 hedge funds and large institutions have $13.6M invested in BioLineRX in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
10% more funds holding
Funds holding: 21 → 23 (+2)
20% less capital invested
Capital invested by funds: $17M → $13.6M (-$3.38M)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Menta Capital
San Francisco,
California
|
+$58.1K |
| 2 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$48.1K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$31.5K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$31.5K |
| 5 |
SM
Senvest Management
New York
|
+$28.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$480K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$388K |
| 3 |
Morgan Stanley
New York
|
-$101K |
| 4 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$19K |
| 5 |
Jane Street
New York
|
-$8.3K |
BLRX Hedge Fund Activity: Q4 2015 in Review
23 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2015, worth a combined $13.6M — down 20% from $17M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BLRX positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Menta Capital, adding an estimated $58.1K. The largest seller was Alyeska Investment Group, cutting an estimated $480K.
- 23 institutional investors held BioLineRX (BLRX) as of Q4 2015, up from 21 in Q3 2015.
- Funds reported $13.6M of BioLineRX stock for Q4 2015, down 20% quarter-over-quarter.
- 4 funds opened new BioLineRX positions in Q4 2015 and 2 closed out, a net change of +2 holders.
- The largest BioLineRX buyer in Q4 2015 was Menta Capital, an estimated $58.1K added.
- The largest BioLineRX seller in Q4 2015 was Alyeska Investment Group, an estimated $480K sold.
Based on aggregated 13F filings for Q4 2015.